

Docket No.: 11987-00043-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Klaus Benke

Application No.: 10/580,711

Confirmation No.: 3892

Filed: May 18, 2007

Art Unit: 1617

For: PROCESS FOR THE PREPARATION OF A
SOLID, ORALLY ADMINISTRABLE
PHARAMACEUTICAL COMPOSITION

Examiner: D. Browe

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)). No fee is therefore believed to be due.

Pursuant to 37 CFR 1.704 (d) (**Reduction of period of adjustment of patent term**), this paper should not be considered to be a failure to engage in reasonable efforts to conclude prosecution. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this

communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2). Translations are submitted for the German-language items.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.97(e) and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 11987-00043-US from which the undersigned is authorized to draw.

Dated: June 1, 2011

Respectfully submitted,

Electronic signature: /Christine M. Hansen/
Christine M. Hansen

Registration No.: 40,634
CONNOLLY BOVE LODGE & HUTZ LLP
1007 North Orange Street
P. O. Box 2207
Wilmington, Delaware 19899-2207
(302) 658-9141
(302) 658-5614 (Fax)
Attorney for Applicant